undefined undefined
NaN.000
NaN.00%
Data released over the weekend showed that China’s consumer price index rose 0.3% y/y last month, accelerating from a 0.1% rise in March, which was also the consensus forecast. Meanwhile, producer pri...
05-13 14:57
In the last three months, 5 analysts have published ratings on Valneva (NASDAQ:...
05-08 21:00
A private survey showed that factory growth hit a 14-month high this month. The Caixin China General Manufacturing PMI increased to 51.4 in April 2024 from 51.1 in the previous month, beating estimat...
04-30 15:23
China’s economy expanded 5.3% in the first quarter from a year ago, higher than the 5.2% seen in the previous quarter and beating expectations for a 5% growth, lifted by continued support measures fro...
04-16 13:20
The People's Bank of China (PBOC) said that it will set up a 500B yuan ($69.12B) re-lending program to support innovation and project upgrades in the science and technology sectors. The program will ...
04-08 15:52
Valneva press release (NASDAQ:VALN): FY GAAP EPS of -€0.73. Revenue of €153.71 million (-57.5% Y/Y). Valneva’s total product sales reached €144.6 million in 2023 compared to €114.8 million in 2022. Ca...
03-20 16:13
In China, the PBOC kept lending rates at record lows in its monthly fixing as efforts to bolster recovery continued. The 1-year loan prime rate remained at 3.45%, and the 5-year rate stood at 3.95% fo...
03-20 15:45
Updated FY 2024 guidance Valneva raises its 2024 product sales4 guidance to between €160 million and €180 million due to an improved outlook regarding the IXIARO® supply
03-20 14:32
First full year 2024 guidance Product sales expected between €150 million and €180 million, reflecting continued revenue growth for proprietary products and IXCHIQ®'s launch-year sales, despite
02-15 14:36
The Company was awarded a tropical disease PRV in November 20231 following U.S. FDA approval of IXCHIQ®, Valneva's single-dose, live-attenuated vaccine indicated for the prevention of disease caused by
02-05 14:06